Carregant...
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Strict criteria for when to stop tyrosine kinase inhibitor (TKI) therapy in clinical practice are not easily defined without an agreement on what probability of achieving a treatment-free remission (TFR) constitutes a medically acceptable standard and consideration of the potential medical risks of...
Guardat en:
| Publicat a: | Curr Treat Options Oncol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer US
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5842492/ https://ncbi.nlm.nih.gov/pubmed/29520446 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-018-0532-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|